source
- Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trialNovo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…
- Madrigal spends $255 million on multiple MASH drug deals to complement RezdiffraMadrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer…